Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BXRXNASDAQ:CNSPNASDAQ:DRMANASDAQ:MBIO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBXRXBaudax Bio$0.02$0.02$0.01▼$3.47$1.14M1.57281,029 shs310,872 shsCNSPCNS Pharmaceuticals$0.83+0.2%$1.05$0.77▼$200.00$4.54M2.65695,182 shs139,502 shsDRMADermata Therapeutics$0.69-1.9%$0.76$0.65▼$5.00$4.43M0.571.18 million shs132,909 shsMBIOMustang Bio$1.07+4.9%$1.22$1.01▼$42.94$4.68M2.24215,717 shs225,610 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for June 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBXRXBaudax Bio0.00%0.00%0.00%0.00%0.00%CNSPCNS Pharmaceuticals+0.34%-10.56%-35.52%-77.02%-99.31%DRMADermata Therapeutics-1.91%-10.32%-16.37%-41.18%-72.01%MBIOMustang Bio+4.90%-16.41%-7.76%-25.69%-97.48%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBXRXBaudax BioN/AN/AN/AN/AN/AN/AN/AN/ACNSPCNS Pharmaceuticals2.5249 of 5 stars3.35.00.00.02.20.00.6DRMADermata Therapeutics2.1317 of 5 stars3.55.00.00.00.60.80.0MBIOMustang Bio0.205 of 5 stars0.03.00.00.00.60.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBXRXBaudax Bio 0.00N/AN/AN/ACNSPCNS Pharmaceuticals 2.50Moderate Buy$25.002,905.53% UpsideDRMADermata Therapeutics 3.00Buy$3.00332.21% UpsideMBIOMustang Bio 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest BXRX, CNSP, DRMA, and MBIO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/22/2025CNSPCNS PharmaceuticalsAlliance Global PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy5/21/2025DRMADermata TherapeuticsMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$6.00 ➝ $3.003/25/2025CNSPCNS PharmaceuticalsMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold(Data available from 6/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBXRXBaudax Bio$1.27M0.90N/AN/A($14.93) per share0.00CNSPCNS PharmaceuticalsN/AN/AN/AN/A$5.37 per shareN/ADRMADermata TherapeuticsN/AN/AN/AN/A$0.62 per shareN/AMBIOMustang BioN/AN/AN/AN/A($2.11) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBXRXBaudax Bio-$58.79M-$9.23N/AN/AN/AN/AN/A-175.11%N/ACNSPCNS Pharmaceuticals-$14.86M-$3,748.50N/A∞N/AN/A-385.41%-193.20%8/13/2025 (Estimated)DRMADermata Therapeutics-$12.29M-$16.41N/A∞N/AN/A-270.81%-179.96%8/6/2025 (Estimated)MBIOMustang Bio-$15.75M-$78.00N/AN/AN/AN/AN/A-80.79%8/12/2025 (Estimated)Latest BXRX, CNSP, DRMA, and MBIO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025CNSPCNS PharmaceuticalsN/A-$1.58N/A-$1.58N/AN/A5/14/2025Q1 2025DRMADermata Therapeutics-$0.45-$0.45N/A-$0.45N/AN/A5/14/2025Q1 2025MBIOMustang BioN/A-$0.05N/A-$0.05N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBXRXBaudax BioN/AN/AN/AN/AN/ACNSPCNS PharmaceuticalsN/AN/AN/AN/AN/ADRMADermata TherapeuticsN/AN/AN/AN/AN/AMBIOMustang BioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBXRXBaudax BioN/A0.070.07CNSPCNS PharmaceuticalsN/A4.944.94DRMADermata TherapeuticsN/A3.703.70MBIOMustang BioN/A1.341.34Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBXRXBaudax Bio9.05%CNSPCNS Pharmaceuticals14.02%DRMADermata Therapeutics8.67%MBIOMustang Bio9.95%Insider OwnershipCompanyInsider OwnershipBXRXBaudax Bio0.10%CNSPCNS Pharmaceuticals0.07%DRMADermata Therapeutics18.50%MBIOMustang Bio0.21%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBXRXBaudax Bio952.46 million52.41 millionNot OptionableCNSPCNS Pharmaceuticals55.46 million5.46 millionNot OptionableDRMADermata Therapeutics86.38 million5.20 millionNot OptionableMBIOMustang Bio1004.38 million4.37 millionNot OptionableBXRX, CNSP, DRMA, and MBIO HeadlinesRecent News About These CompaniesMustang Bio (NASDAQ:MBIO) Trading Down 5.1% - Should You Sell?June 17 at 1:27 AM | americanbankingnews.comMustang Bio’s first-of-a-kind CAR-T starts trialsMay 1, 2025 | pharmaphorum.comMustang Bio meets Nasdaq’s equity listing requirementsMarch 8, 2025 | investing.comMustang Bio Regains Nasdaq Compliance, Secures Position For Cell Therapy AdvancementsMarch 8, 2025 | nasdaq.comMustang Bio regains compliance with Nasdaq requirementMarch 5, 2025 | markets.businessinsider.comMustang Bio, Inc. Regains Compliance with Nasdaq Capital Market Listing RequirementsMarch 5, 2025 | quiverquant.comMustang Bio Regains Compliance with Nasdaq Capital Market RequirementMarch 5, 2025 | globenewswire.comBRIEF—Mustang Bio sells assets; focuses on MB-109, MB-108 and MB-101March 3, 2025 | thepharmaletter.comMustang Bio exits Worcester facility, sells assets to AbbVieMarch 1, 2025 | uk.investing.comMustang Bio closes Worcester facility, moves HQ to Waltham after reverse stock splitFebruary 28, 2025 | wbjournal.comMustang Bio Ends Manufacturing Facility Lease Hoping to Save, Plans Brain Tumor Cell Therapy TrialFebruary 28, 2025 | precisionmedicineonline.comMustang Bio, Inc.: Mustang Bio Announces Sale of Fixed Assets and Exit of FacilityFebruary 28, 2025 | finanznachrichten.deMustang Bio to Exit Lease of Worcester, Mass. Manufacturing FacilityFebruary 27, 2025 | marketwatch.comMustang Bio exits lease for Massachusetts facility, divests equipmentFebruary 27, 2025 | markets.businessinsider.comMustang Bio stock plunges 29% on lease termination newsFebruary 27, 2025 | msn.comMustang Bio Announces Sale of Fixed Assets and Exit of FacilityFebruary 27, 2025 | globenewswire.comMustang Bio sells assets and ends lease with AbbVieFebruary 13, 2025 | msn.comMustang Bio stock plunges to 52-week low of $2.6 amid sharp declineFebruary 13, 2025 | msn.comMustang Bio regains compliance with NasdaqFebruary 11, 2025 | markets.businessinsider.comMustang Bio, Inc. Regains Compliance with Nasdaq Listing Requirements Following Recent Public OfferingFebruary 11, 2025 | quiverquant.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBXRX, CNSP, DRMA, and MBIO Company DescriptionsBaudax Bio NASDAQ:BXRXBaudax Bio, Inc., a pharmaceutical company, develops and commercializes products for hospital and other acute care related settings. The company offers ANJESO (meloxicam) injection for the management of moderate to severe pain, alone or in combination with other non-NSAID analgesics. It also develops BX1000, an intermediate-acting neuromuscular blocking agent (NMB) that is in phase II clinical trial; BX2000, an ultra- short acting NMB, which is in phase I clinical trial, as well as a proprietary blockade reversal agent; and BX3000, a NMB reversal agent that is in preclinical studies. Baudax Bio, Inc. was incorporated in 2019 and is based in Malvern, Pennsylvania.CNS Pharmaceuticals NASDAQ:CNSP$0.83 +0.00 (+0.22%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$0.83 0.00 (-0.22%) As of 06/18/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc., Reata Pharmaceuticals, Inc., Pomeranian Medical University, and The University of Texas M.D. Anderson Cancer Center; and a development agreement with WPD Pharmaceuticals Inc. The company was incorporated in 2017 and is based in Houston, Texas.Dermata Therapeutics NASDAQ:DRMA$0.69 -0.01 (-1.91%) Closing price 06/18/2025 03:49 PM EasternExtended Trading$0.69 -0.01 (-1.02%) As of 06/18/2025 07:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Dermata Therapeutics, Inc., a late-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea. It is also developing DMT410 that has completed Phase Ib POC trials for the treatment of anxillary hyperhidrosis and aesthetic conditions. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.Mustang Bio NASDAQ:MBIO$1.07 +0.05 (+4.90%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$1.08 +0.01 (+1.40%) As of 06/18/2025 06:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors. The company develops MB-117 and MB-217, a gene therapy program for X-linked severe combined immunodeficiency, a rare genetic immune system condition in which affected patients do not live beyond infancy without treatment. The company also develops MB-106 CAR T cell program for B cell non-hodgkin lymphoma and chronic lymphocytic leukemia; MB-101 CAR T cell program for glioblastoma; MB-108, a next-generation oncolytic herpes simplex virus. It has license agreements with Nationwide Children's Hospital, CSL Behring; Mayo Clinic; Leiden University Medical Centre; SIRION Biotech GmbH. The company was incorporated in 2015 and is headquartered in Worcester, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Robinhood Director Sells Millions, But HOOD Stock Eyes Gains Coinbase Stock Pops as Senate Passes GENIUS Stablecoin Bill Chime’s Smart IPO: Half the Valuation, Double the Strength 3 Tech Stocks With High and Rising Institutional Interest Salesforce Raises Prices: 3 Reasons Its Stock Price Will Follow Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
